Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients

BACKGROUND. Recombinant human PDGF-BB (rhPDGF-BB) reduces Parkinsonian symptoms and increases dopamine transporter (DAT) binding in several animal models of Parkinson’s disease (PD). Effects of rhPDGF-BB are the result of proliferation of ventricular wall progenitor cells and reversed by blocking mi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Invest
Asıl Yazarlar: Paul, Gesine, Zachrisson, Olof, Varrone, Andrea, Almqvist, Per, Jerling, Markus, Lind, Göran, Rehncrona, Stig, Linderoth, Bengt, Bjartmarz, Hjalmar, Shafer, Lisa L., Coffey, Robert, Svensson, Mikael, Mercer, Katarina Jansson, Forsberg, Anton, Halldin, Christer, Svenningsson, Per, Widner, Håkan, Frisén, Jonas, Pålhagen, Sven, Haegerstrand, Anders
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2015
Konular:
Clinical Medicine
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4362250/
https://ncbi.nlm.nih.gov/pubmed/25689258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI79635
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller